CNS Licensing Trends: Volume Falls, Values Rise

According to a new analysis from Datamonitor Healthcare, the volume of deals in the CNS space has fallen since 2012 but the overall value of alliances is increasing, particularly when it comes to up-front payments for potential Alzheimer's therapies.

Human brain — 2016 saw fewer CNS alliances overall but deal values are on the rise • Source: Shutterstock

Licensing deals involving drugs for central nervous system conditions were worth more in 2016 than previous years, although there are fewer agreements being signed in this disease space. One of the most lucrative CNS pacts since 2012 was AbbVie Inc. and Google-funded start-up Calico Life Sciences LLC's arrangement for new treatments targeting Alzheimer's and other diseases related to aging.

According to new research from Datamonitor Healthcare, from 2012 through 2015 the total potential deal value for CNS therapies each...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

04 Jun 2025

• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

03 Jun 2025

• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

02 Jun 2025

• By Kevin Grogan

But the French major is still keen on early-stage M&A.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

30 May 2025

• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

11 Jun 2025

• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.